BioAsia 2009 Event Report

R

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

A Report

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

Preface It gives me immense pleasure to bring out this report on BioAsia 2009: The Global Biobusiness Forum held at Hyderabad from February 1 - 4, 2009 at Hyderabad to you. The event was organized by Federation of Asian Biotech Associations [FABA] in association with All India Biotech Association, Government of Andhra Pradesh and University of Hyderabad.

As you may be aware, BioAsia is an annual international event being held at Hyderabad, India assisting biotech and biopharmaceutical industry since 2004 to create new business partnership, academic collaborations and for exploring and sharing resources.

BioAsia 2009 emerged as one the most successful events witnessing a large participation from key global players in Biotech/ Biopharma/ BioAgri sectors across the world despite the global recession.

Besides, BioAsia achieved a milestone of realizing 280 private one-to-one meetings during the three days, a four fold increase compared to the previous BioAsia.

An exclusive parallel track during all the three days on Agribiotechnology was introduced for the first time in BioAsia. Genome Valley Excellence Award 2009 was bestowed upon two stalwarts Prof.

Marc Van Montagu, Founder Chairman, Institute of Plant Biotechnology for developing countries, Belgium and Dr. Martin Mackay, President, Pfizer Global Research and Development, USA for their outstanding contribution in the field biotechnology.

BioAsia Innovation Award for young scientists below the age of 35 years was first introduced in the year 2007. The award for 2009 consisting of INR 1 Lac and a citation was presented during the event to Dr. Sunil Kumar Verma, Center for Cell and Molecular Biology for his innovative research on “Novel Universal technique to establish the identity of enormous number of animal species for forensic application�. Besides, another award for the school children of standards 10th, 11th and 12th class, called BioAsia Young Minds Award was instituted for novel concepts from students for the first time in BioAsia. Ms. Abinaya, a 12th standard student from Chennai clinched this award which consisted of a citation and INR 50,000/- for her project on marine actinomycetes.

BioAsia 2009 attracted a wide range of entrepreneurs including senior executives of leading Biotech companies, business development teams from large and midsize Pharmaceutical companies, eminent scientists from R & D institutions and universities, investors and other industry experts, etc.

Furthermore, the special events at BioAsia 2009 Viz. Bioparks Session and CEO Conclave turned out to be a grand success.

I express my gratitude to my colleague Mr. N. Shakthi Meyyappan for his help in preparing this report.

Looking forward to your continued support.

Dr. B. S. Bajaj Convener-BioAsia 2009 Chairman-AIBA-SC Secretary General- FABA

Supported by

Event Co-Sponsor

CEO Conclave Sponsor

Gold Sponsor

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

Highlights of BioAsia 2009 1. Inaugurated by the Hon'ble Chief Minister of Andhra Pradesh, Dr. Y S Rajasekhara Reddy 2. Genome Valley Excellence Award to Prof. Marc Van Montagu and Dr. Martin Mackay 3. Presence of two overseas Ministers Viz. Sri Lanka & Spain and the British High Commissioner 4. 280 private B2B meetings realized during the three days and 290 meeting requests still in the pipeline 5. Participation of 20 Countries despite the global economic meltdown with about 91 overseas delegates 6. US Delegation (25) and Iranian Delegation (18) were the highest delegations 7. Participation of Global Biopharma and Biotech Majors/ MNCs Viz. • Pfizer (USA) • Lonza (Switzerland) • Genentech (USA) • Merck & Co. (USA) • Actelion (Switzerland) • Avesthagen (India) • Biocon (India) And many more….

8. Two tracks and 17 sessions with 72 speakers/ panelists for the first time 9. Parallel Agri sessions on all the three days with about 25 speakers in 8 sessions 10. Memorandum of Understanding signed between BioCat (Spain), Federation of Asian Biotech Associations and Andhra Pradesh Industrial Infrastructure Corporation for cooperation in various areas of Biotech/ Biopharma sectors.

11. BioAsia Young Minds Award consisting of INR 50, 000 and a citation th awarded to Ms. Abinaya of 12 Standard and BioAsia Innovation Award INR One Lac and a citation to Dr. Sunil Kumar Verma from CCMB

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

Delegates - Countries of Origin Countries USA Switzerland Spain Germany Belgium Austria Australia Canada Malaysia Kenya China Japan Sri Lanka Iran U.K. Netherlands Denmark Brazil Singapore India Total

No. of Delegates 25 6 6 5 2 1 1 2 6 1 1 2 3 18 5 2 2 1 3 299 390

Students - States/ Countries of Origin States/ Countries

No. of Students

New Delhi

34

Maharashtra

10

Kerala

13

Tamil Nadu

11

AP (Hyderabad)

99

Karnataka

2

Punjab (Chandigarh)

1

Uttarakhand (Roorkee) UP (Lucknow)

1 1

Iran

1

USA

1 Total

174

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

B2B MEETINGS B2B Associate: PharmABC, Germany •

No. of B2B meetings realized during the three days -

:

280

No. of B2B meetings pre-scheduled online prior to the event : 152 No. of B2B meetings scheduled on site during the event : 128

•

No. of meetings requested by delegates

:

665

•

No. of meeting requests still pending

:

290

•

For the first time in BioAsia history, 152 B2B-meetings have been prescheduled prior to the partnering event and 280 meetings have been realized during the three days

•

The partnering area featured 10 meeting locations; open for private meetings from 10am to 5pm (Monday, Tuesday) and 9am to 2. 30 pm (Wednesday)

•

Participants have been offered a dedicated partnering desk which assisted them in all practical issues re. their B2B-partnering activities -

on spot registration welcome pack with introduction to B2B partnering, catalogue etc regular updates of partnering agenda re-scheduling of meetings no-show management

Private One-to-One B2B Meeting

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

B2B Meetings (Contd.)

Distribution of participants by origin India Rest of Asia Europe North America Africa Total

North America 9%

97 20 19 13 1 150

Africa 1%

Europe 13%

Rest of Asia 13%

India 64%

Participants by type of organisation Organisation Industry Professional services Research & Education Technology transfer & Innovation management Public Organisations Investors Press & Media Other

Percentage 42% 21% 12% 9% 7% 7% 2% 5%

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

B2B Meetings (Contd.)

Participants by sector Human Health

56%

Agro-Food

30%

Environment & Industry

14%

Participants by management level Corporate management

72%

Business management

13%

Project management

10% 5%

Staff

Qualitative distribution of participants by sector and type of organisation Agro - Environment Human Other Total Food & Industry Health 87 19 4 44 20 13 4 3 3 3 47 10 8 16 13 22 7 5 7 3 23 5 4 7 7

Industry Investors Professional Services Public Organisations Technology Transfers and Innovation Management Research and Education Press & Media Other (Yet not classified) Total

9 1 3 58

4 0 2 30

10 3 2 92

2 1 1 50

Overview Indian participants Industry

39

Investors

5

Professional services

24

Public organizations Technology Transfer & Innovation management

4 7

Research & Education

13

Press & media

1

Other

4 Total

97

25 5 8 230

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

B2B Meetings (Contd.)

Comparison of B2B Meetings over the past three BioAsias BioAsia 2007 2008 2009

No. of B2B Meetings 43 70 280

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

Hon’ble Minister of Major

Industries, Sugar, Commerce & Export Promotion, Government of AP , Dr. J. Geeta Reddy interacting with an exhibitor in the international tradeshow

Presentation by an exhibitor in the tradeshow area

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

AWARDS

Genome Valley Excellence Award - 2009 Genome Valley Excellence Award 2009 was conferred by the Hon'ble Chief Minister of Andhra Pradesh, Dr. Y S Rajasekhara Reddy during the Inaugural Session of BioAsia 2009 to two eminent personalities in the field of Biotechnology: 1. PROF. MARC VAN MONTAGU, Founder and Chairman, Institute of Plant Biotechnology for Developing Countries, Belgium for •

Discovering the gene transfer mechanism between Agrobacterium and plants, together with his colleague Prof. Jeff Schell, which resulted in the development of methods to alter Agrobacterium into an efficient delivery system for gene engineering and to create transgenic plants

•

Developing plant molecular genetics, in particular molecular mechanisms for cell proliferation and differentiation and response to abiotic stresses (high light, ozone, cold, salt and drought)

•

Constructing transgenic crops (tobacco, rape seed, corn) resistant to insect pest and tolerant to novel herbicides.

•

His work with poplar tree resulting in improved pulping qualities

2. DR. MARTIN MACKAY, President, Pfizer Global Research and Development (PGRD), USA for •

His pivotal role in forming the world's largest private biomedical research organization comprising over 13,000 employees

•

His stewardship role in increasing the number of Pfizer biotechnology products from a single compound to over 25 in the last decade

•

Establishing 'Asia Pharma R & D' Function, involving China and India as major participant nations

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

(Awards Contd.)

BioAsia Innovation Award 2009 No. of proposals received No. of proposal shortlisted Award Winner Topic

: : : :

Award

:

22 10 Dr. Sunil Kumar Verma, CCMB Novel Universal technique to establish the identity of enormous number of animal species for forensic application Citation and Cash Award (INR 1 Lac)

BioAsia Young Minds Award 2009 (Introduced for the first time in BioAsia) No. of proposals received No. of proposal shortlisted Award Winner

: : :

Topic Award

: :

11 5 Ms. B. Abinaya, XII, Sri Sankara Senior Secondary School, Chennai Project on Marine Actinomycetes Citation and Cash Award (INR 50,000)

: : :

Vibha Seeds, Hyderabad Lonza, Switzerland Matrix , Hyderabad

Stall Awards Winner First Runner Up Second Runner Up

MEDIA COVERAGE Print Media Preconference reports Conference report Total National Media Local Media Metros

: : :

45 44 89 57 32 55

Media Coverage

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

Media Coverage (Contd.)

Print Media

No. of Reports

Business Standard

7

Sakshi

11

Financial Express

9

Asian Age

1

The Hindu

13

Andhra Prabha

6

Web India 123

1

Hindu Business Line

10

Hindi Milap

3

Deccan Chronicle

5

Eenadu

4

Andhra Bhoomi

1

Andhra Jyothi

2

DNA

2

Surya

3

Vaartha

5

Economic Times

1

Times of India

4

Siasat

1 Total

89

Electronic Media Preconference Clips : Conference Clips : Total :

1 10 11

1 2 1

TV5 HMTV MAA TV

1 1

Local TV TV5

1 1

Gemini CNBC

Total

11

CONFERENCE

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

Programme Feb 1, 2009 – Preconference 09.30 - 13.00 Bioparks Session 17.00 – 18.25 Inaugural Session 18.25 – 18.45 High Tea 18.45 – 19.45 Distinguished Lectures 19.45 – 21.00 Biobanquet Dinner February 02, 2009 – Day 1 Time (Hrs) Track I Track II (Agri Biotech) 09:30 - 11:00 Session I Session II Business Drivers leading to Crop Biotechnology: Scope and Collaborations & Licensing Challenges 11:00 - 11:30 Tea/ Coffee Break 11:30 - 13:00 Session III Session IV Innovative solutions to Funding Food Technology: Human Health and challenges safety 13:00 -15:00 Lunch & Visit to Exhibition (Short Presentation by some Industries in tradeshow area) 15:00 -16:30 Session V Session VI Partnerships in Drug Discovery in Seed Technology: An important Asian Countries: Case Studies Industry in developing Countries 16:30 Onwards Tea/ Coffee Break and Visit to Exhibition (Short Presentation by some Industries in tradeshow area) 19:30 - 21.30 CEO’s Conclave & Dinner (Only for CEO’s & invitees) February 03, 2009 – Day 2 09:00 - 11:00

Session VII Oncology & Monoclonal Antibodies 11:00 - 11:30 Tea/ Coffee Break

Session VIII Phytopharmaceuticals

11:30 - 12:00

Session X Biofuels

Session IX Vaccines: India’s Strength

13:00 -15:00 Lunch & Visit to Exhibition (Short Presentation by some Industries in tradeshow area) 15:00 - 16:30 Session XI Session XII Service Sectors (CROs, CMOs & Animal improvement and Genomics `Outsourcing) 16:30 - 17:00 Tea/ Coffee Break 17:00 - 19.00 Session XIII Session XIV Nanotechnology and CADD approaches Animal Biotechnology: Diagnostics and for drug discovery Vaccines February 04, 2009 – Day 3 09:00 - 10:30 Session XV Session XVI Stem Cell Research Scenario in India Agri Biotech Platform: Products and Services 10:30 - 11:00 Tea/ Coffee Break 11:00 - 12:30 Session XVII Manpower Challenges in Biotechnology 12:45 - 13:30 Valedictory Session

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

INAUGURAL CEREMONY OF BIOASIA 2009 The event was inaugurated by the Hon'ble Chief Minister, Government of Andhra Pradesh, Dr. Y S Rajasekhara Reddy and presided by Dr. J. Geeta Reddy, Hon'ble Minister of Major Industries, Sugar, Commerce & Export Promotion, Government of Andhra Pradesh. Prof. Seyed E Hasnain, Vice Chancellor, University of Hyderabad, Chairman, AP Biotech Advisory Council and BioAsia 2009 Advisory Board, welcomed the gathering which was followed by the addresses by the Guests of Honour Prof. Tissa Vitarana, Hon'ble Minister for Science & Technology, Govt. of Sri Lanka, Dr. Manel Balcells, Hon'ble President, BioRegion of Catalonia, Former Minister of Research and Innovation, Govt. of Catalonia, His Excellency, Sir Richard Stagg, British High Commissioner as Guests of Honour.

The Hon'ble Chief Minister unveiled the logo of Knowledge and Innovation Park, which is Joint venture between University of Hyderabad and Andhra Pradesh Industrial Infrastructure Corporation, at Hyderabad. Besides, the Hon'ble Chief Minister unveiled the plaque to mark the inauguration of New Vaccine Facility of Biological E in S.P Biotech Park, Phase II, Hyderabad. Later the Genome Valley Excellence Award 2009 was presented by the Hon'ble Chief Minster to Prof. Marc Van Montagu and Dr. Martin Mackay in recognition of their contributions to the biotech research/ industry.

Dr. J. Geeta Reddy launched the AP Wing of National Biological Association for Students [NBAS] which is the student body of All India Biotech Association and delivered the presidential address.

Dr. B. S. Bajaj, Convener, BioAsia 2009, Chairman, AIBA-SC and Secretary General, FABA delivered the vote of thanks which was followed by a short tea/ coffee break.

More than 700 delegates participate in the inaugural ceremony.

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

(L to R) : Prof. Seyed E Hasnain, Dr. Martin Mackay, Prof. Marc Van Montagu, Hon’ble Prof.

Tissa Vitarana, Hon’ble Dr. Y S Rajasekhara Reddy, Hon’ble Dr. J. Geeta Reddy, His Excellency Sir Richard Stagg, Hon’ble Dr. Manel Balcells and Dr. B. S. Bajaj

Unveiling the logo of Knowledge and Innovation Park (L to R): Prof. Seyed E Hasnain, Hon’ble Dr. Y S Rajasekhara Reddy, Hon’ble Dr. J. Geeta Reddy, Mr. B. P. Acharya, I.A.S

Unveiling the plaque to mark the inauguration of New Vaccine Facility of Biological E (L to R): Ms. Mahima, Hon’ble Dr. Y S Rajasekhara Reddy, Hon’ble Dr. J. Geeta Reddy and His Excellency Sir Richard Stagg

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

Hon’ble Dr. Y S Rajasekhara Reddy presenting the Genome Valley Excellence Award to Prof. Marc Van Montagu

Hon’ble Dr. Y S Rajasekhara Reddy presenting the Genome Valley Excellence Award to Dr. Martin Mackay

Hon’ble Dr. J. Geeta Reddy launching the AP Chapter of the National Biological Association for Students, The Student wing of All India Biotech Association

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

DISTINGUISHED LECTURES The inaugural plenary resumed with the distinguished lectures by Dr. Martin Mackay on “Directed Evolution of Pharmaceutical and Biotherapeutic R&D” and Mr. Stefan Borgas, CEO, Lonza, Switzerland on “Global biomanufacturing in a challenging time - Delivering sustainable values while weathering out the perfect storm” which kindled the minds of the participants. Biobanquet dinner followed this inaugural plenary.

Dr. Martin Mackay

(L to R): Mr. Acharya, Prof. Seyed E Hasnain and Mr. Stefan Borgas

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

TRACK I BUISINESS DRIVERS LEADING TO COLLABORATIONS & LICENCING Sponsored by Merck & Co. Inc, USA Chairman: Dr. Swaminathan Subramaniam, Director, Licensing & External Research, Merck & Co., Inc., India Speakers: 1.

2.

3.

Dr. Reid Leonard, Executive Director, Licensing & External Research, Merck & Co., USA Prof. Brian F Clark, Vice President, European Federation of Biotechnology, Barcelona Dr Ravi Sodha, Senior Director, Business Development, Actelion Pharma, Switzerland

All the speakers presented various examples from their individual companies of challenges and opportunities in collaborative ventures for unmet medical needs. Merck's global licensing interests and partnering opportunities that fit Merck's strategic research and development objectives were presented by Dr. Subramaniam and Dr. Leonard. The role of European Federation of Biotechnology to advance sustainable and beneficial, use of life sciences was elaborated by Prof. Clark who added that such collaborations could be extended to Indian Biotechnologists. Dr. Sodha emphasised the importance of licensing activities for the growth of emerging market trends.

(L to R): Dr. Subramaniam, Dr. Ravi Sodha, Dr. Haleh Hashemi, Dr. Prof. Brian F Clark and Dr. Reid Leonard

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

INNOVATIVE SOLUTIONS TO FUNDING CHALLENGES Chairman: Mr. Sarath Naru, Managing Partner, APIDC Venture East, Hyderabad Moderator: Dr. Aditya Kapil, Principal, APIDC Venture East, Hyderabad Panelists: 1.

2.

3.

4.

Dr. Jasmin Patel, Managing Director, Fidelity India Capital, Mumbai Dr. Prasad Sunkara, Advisor, M&A Group, Rodman & Renshaw LLC, USA Dr. Chris Lowe, Director, Institute of Biotechnology, Cambridge University, UK Dr, Anand Govindaluri, Exectuve Director and Chief Investment Officer, Fortunis Ventures Pvt Ltd, Singapore

The panel discussed India's role in business development and the increasing responsibility of the venture capitalists in funding the pharma and other biotech companies. They discussed the funding mechanisms in various areas including R&D strategies, new product commercialisation, marketing strategies, organizational designs and business developments.

This session was thrown open to the audience for interaction and Q&A. Further this session was preceded by a presentation by Dr Chris Lowe of Cambridge University U.K. who elaborated the role of academia in process and product development.

(L to R): Mr. Sarath Naru, Dr. Jasmin Patel, Dr. Chris Lowe, Dr, Anand Govindaluri Dr. Aditya Kapil and Dr. Prasad Sunkara

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

PARTNERSHIPS IN DRUG-DISCOVERY IN ASIAN COUNTRIES: CASE STUDIES Chairman: Dr. Krishna M. Ella, Chairman and Managing Director, Bharat Biotech Ltd., Hyderabad Moderator: Dr Swapan Bhattacharya, MD, TCG Life Sciences, Bangalore Panelists: 1. Dr Rashmi Barbhaiya, MD & CEO Advinus Therapeutics, Bangalore 2. Dr. Hartmut Kühn, University Medicine Berlin, Charité, Manhijoustr., Berlin, Germany 3. Dr. Manni Kantipudi, GVK Bio, Hyderabad 4. Mr. Hitesh Sharma, Partner & Leader (Health Sciences), E & Y, Hyderabad This session was a panel discussion on how academia and companies can come together to share knowledge and competence for drug discovery process. Managing professional servicing and IT needs in India were more challenging compared to other countries. Issues like ethics were also brought out and discussed in depth. The funding for drug-discovery process and time-line for the products to be short-listed and then selected for clinical trials were spelled out by the panelists. Issues relating to Patents and IPRs were also discussed.

(L to R): Dr. Manni Kantipudi, Dr Rashmi Barbhaiya, Dr. Krishna M. Ella, Dr Swapan Bhattacharya, Mr. Hitesh Sharma, Dr. Hartmut Kühn and Mr. Kali Prasad

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

ONCOLOGY AND MONOCLONAL ANTIBODIES Chairman: Dr. Robert W. Naismith, Chairman & CEO, Roosevelt Capital Partners, LLC, PA, USA Speakers: 1. Dr. Vijay Ramakrishnan, Founder & CEO, PIKAMAB Inc, CA, USA/ Dr. Janet McNicholas, Partner, Bell, Boyd & Lloyd, USA 2. Dr. Amitabha Chaudhuri, Scientist, Genentech, CA, USA 3. Dr. Shireen Vali, Cellworks Group Inc., CA, USA 4. Dr. Barry Furr, Former Chief Scientist, AstraZeneca, UK In this session targeted therapy approaches for oncological solutions were discussed by distinguished speakers, who came forward to present their individual experience. Several case studies on mapping tumour signatures for personalized medicine were discussed.

These included several monoclonal antibodies, as they are very specific to their targets.

Monoclonal antibodies have emerged as a promising class of therapeutics to treat various cancers and autoimmune diseases. The market for the monoclonals is now expanding and has already crossed US $3.0 billion mark in 2007. Recognising the importance of monoclonal antibodies for cancer therapy PIKAMAB of USA has collaborated with Bell, Boyd & Lloyd for global patents. Dr. Janet informed the gathering of the intellectual property matters relating to recombinant biologicals, therapeutic antibodies, bioprocessing and bioproducting pharmaceuticals. Dr. Choudhuri also presented some basic research work on novel targeted therapies, and use of biomarkers in understanding the biology of cancer, which lead to the development of targeted therapies.

(L to R): Dr. Kaiser Jamil, Dr. Robert W. Naismith, Dr. Amitabha Chaudhuri, Dr. Vijay Ramakrishnan, Dr. Janet McNicholas, Dr. Shireen Vali, Dr. Barry Furr and Prof. Reddanna

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

VACCINES : INDIA'S STRENGTH Sponsored By Shantha Biotechniques, Hyderabad Chairman: Dr. K. I. Varaprasad Reddy, CEO, Shantha Biotechniques, Hyderabad Speakers: 1. Dr. Albrecht Laufer, Corvay GmbH, Germany 2. Dr. Martin Gotting, Vice President, Intercell AG, Austria 3. Dr. Raman, VP, Scientific & Medical Affairs, Shantha Biotechnics Ltd, Hyderabad 4. Dr. Srinivasan Chandrasegaran, Johns Hopkins Medical Institutions, Baltimore, USA Vaccination is the most successful medical intervention, which has become a mandatory part of healthcare programs of many countries. This session dealt with the prospects of manufacturing novel cell culture products and recombinant technologies. Dr. Martin Goetting elaborated the concepts of the expanding spectrum of vaccines with the advent of conjugation, protein expression and cell culture technologies stating examples like HiB which is the conjugated pneumo, the HBV and the HPV vaccines which have set a new standards in the vaccine world and provided the means to reduce heavy mortality and disease related disabilities for millions of people. Another novel technology has been in the vaccine delivery area, with the advent of skin patch deliver known as “panflu�. Dr Varaprasad Reddy showcased the vaccine scenario through a video-film showing many firsts in vaccine production by Shantha Biotech and reported India's strength in this direction. Innovation in vaccine development is driven by small and medium sized enterprises that partner with leading vaccine players of the developed world and move successfully into the global markets

(L to R): Dr. Albrecht Laufer, Dr. K. I. Varaprasad Reddy, Dr. Martin Gotting, Dr. Raman and Dr. Srinivasan Chandrasegaran

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

SERVICE SECTORS (CROs, CMOs & OUTSOURCING) Chairman: Prof. C. Channa Reddy, Director Emeritus, Huck Institutes of the Life Sciences, Penn. State University, USA Speakers: 1. Ms. Jumana Barnagarwala, Principal Consultant, Healthcare, Datamonitor, India 2. Dr. John M Hyde, Chairman & Founder, Hyde Engineering & Consulting, Inc., USA 3. Dr. Nanda P.B.A. Kumar, Reed Smith LLP, USA

This session covered various topics on biopharmaceuticals business, and the various activities that are outsourced to build India's strength. Various speakers dealt with the issues related to various deals and alliances, which are important and need to be analysed in order to better understand the trends that are prevalent in this business. Biopharma manufacturers are faced with many challenges in producing their products and testing them for drug development for clinical trials for which a good understanding the areas of evaluation procedure and contract research will assist manufacturers in planning and strategizing for audits. Choosing a contract manufacturer for partnering or partnering with CROs and CMOs has been discussed in this session.

(L to R): Prof. Channa Reddy, Dr. Nanda Kumar, Dr. John Hyde, Prof. Reddanna and Ms. Jumana Barnagarwala

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

NANOTECHNOLOGY AND CADD APPROACHES FOR DRUG DISCOVERY Chairman: Prof. Reddanna, School of Life Sciences, University of Hyderabad Speakers 1. Dr. D. Rambhau, Advisor-NDDD, Natco Pharma Limited, Hyderabad 2. Dr. Rami Reddy Mutyala, Co-founder and Chairman, RR Labs Inc, SanDiego, USA

The emergence of novel nanomaterials with exciting biological related applications was discussed. Conventional nano-carriers like emulsions, vesicles, micro-emulsions, micels nano-capsules, self emulsifying systems, which carry good amount of drug payloads are being used to protect sensitive drug molecules from the inactivation by aggressive biological environment and to improve drug delivery to the exact site of the disease. Prof. Devraj Rambhau presented a very elegant and most exiting lecture on the use of nanotechnology in drug delivery, and elaborated on the aspects of enhanced permeability and retention effect of using ligand mediated active targeting, while the intracellular delivery could be mediated by certain internalised ligands or by cell-penetrating peptides. He further talked about the nanocarriers, which can be developed by grafting their surface with water-soluble polymers with flexible main chain. Their experience with antioxidants as targeting ligands were discussed. Dr. Rami Reddy introduced the topic of computer aided drug designing methods and structural Bioinformatics in the discovery of a new class of clinical candidates for diabetes.

(L to R): Dr. Rambhau, Dr. Rami Reddy, Dr. Kaiser Jamil and Prof. Reddanna

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

STEM CELL RESEARCH SCENARIO IN INDIA Sponsored by Department of Biotechnology, Govt. of India, New Delhi through LV Prasad Eye Institute (LVPEI), Hyderabad Chairman: Dr. D. Balasubramanian, Director (Research), LVPEI, Hyderabad Speakers 1.

2.

3.

4.

Dr. Alka Sharma, Joint Director / Scientist E, DBT, New Delhi Dr. Geeta K. Vemuganti, LVPEI, Hyderabad Dr. Sujata Mohanty, AIIMS, New Delhi Dr. Deepa Bhartiya, NIRRH, Mumbai

Dr Alka Sharma gave a bird'e eye view of the activities of DBT in promoting stem cell research in the country including the funding opportunities, fellowships and grants. She also emphasized on the use of combined guidelines of DBT and ICMR in conducting SC research of all types- basic, pre-clinical and clinical Dr Geeta K Vemuganti's work on the largest clinical trial of cell based therapy related to ocular surface reconstruction came out as a unique model of regenerative medicine. This work showcased the type of cell culture technique, various methods to characterize them, method of cell therapy following the guidelines laid by NIH and then going ahead to provide proof of cell survical and integration. She also talked about their novel method of co-culturing limbal and conjunctival cells for severe ocular surface diseases, reported of a new source of mesenchymal cells from limbal stroma and the possibility of developing a 3 D cornea using a new scaffold.

Dr Sujata Mohanty talked about the role of autologus bone marrow mononunclear cell therapy for various conditions like myocardial infarction, cardiomyopathies and ischemic limb disease. The method of isolating the cells and cell delivery has been standaridized, with interim recovery of target tissues, however the long term results and mode of action is still being evaluated. She also share their initial results of limbal cultures specially on nanoparticle scaffolds.

Dr Deepa Bhartiya shared their experience in developing ES Cells using fetal fibroblasts and the methods used to characterize these ES cells. There are in the process of differentiating them into various lineages. She also share the data on techniques of Somatic cell nuclear transfer in sheep model, parthenogenesis. She also initiated work on developing clones from non-human primates which is under progress and awaiting permission from the DBT for further progress.

Prof D Balasubramanian concluded the session highlighting the contribution of women scientists in this field in India.

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

(L to R): Dr. Deepa Bhartiya, Dr. Kaiser Jamil, Dr. Alka Sharma, Prof. Balasubramanian, Dr. Bajaj, Dr Geeta Vemuganti and Dr. Sujata Mohanty

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

MANPOWER CHALLENGES IN BIOTECHNOLOGY Chairman: Prof. V. S. Rao, Director, Birla Institute of Technology and Science, Hyderabad Co-Chairman: Prof. A. R. Reddy, Vice Chancellor, Yogi Vemana University, Kadappa, AP Moderator: Mr. Suresh Narayanan, Chief Editor, Biospectrum, Bangalore Panelists: 1. Dr. S. R. Rao, Scientist G, DBT, Govt. of India, New Delhi 2. Dr. Shrikumar Suryanarayan, DG, Association of Biotech Led Enterprises (ABLE), Bangalore 3. Mr Ravi C Dasgupta, Group HR Head, Biocon, Bangalore 4. Dr. S P Vasireddi, Chairman & Managing Director, Vimta Labs Limited, Hyderabad The panelists discussed the wide spectrum of HR activities and expressed the need for skilled manpower requirement in the biotech sector. They suggested the need for conducting Trainings and workshops before recruitments. Further it was commented that product development was less challenging compared to manpower challenges, as this requires concerted efforts in departing knowledge in ethics and related issues, specially when issues like patenting is considered. Dr. Vasi Reddy a recipient of "Outstanding CRO Management Award" explained about the challenges faced by large companies. This session was an eye opener to a large majority of students and job seekers who were keen to hear the from the panel the requirements of manpower and what the companies are looking at before recruitments

(L to R): Dr. Vasireddi, Prof. V. S. Rao, Mr. Suresh Narayanan, Dr. S. R. Rao, Dr. Shrikumar Suryanarayan and Mr Ravi Dasgupta

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

TRACK II BioAsia 2009 was unique since it comprised of a separate track on Agricultural Biotechnology thereby recognizing that Agribusiness is an important industry in India as well as all the developing countries of Asia. In India, Agriculture contributes in a major way to the national GDP involving over 70% of the population in some or the other way with Agriculture. We are glad to have considered Agribiotechnology with an equal emphasis in BioAsia 009.

The Agribiotechnology Track comprised of 8 concurrent sessions with about 25 speakers.

The deliberations of these sessions are summarized below: CROP BIOTECHNOLOGY SCOPE AND CHALLENGES Sponsored by: International Service for the Acquisition of Agri-biotech Applications (ISAAA) Chairman: Prof. VL Chopra, Member, Planning Commission, Govt. of India, New Delhi Speakers: 1. Prof. Marc Van Montagu, Founder and Chairman, Institute of Plant Biotechnology for Developing Countries, Belgium 2. Prof. Heinz Saedler, Director, Max-Planck Institute, Koln, Germany 3. Dr. Robert Tuberosa, Professor, University of Bologna, Italy Green revolution has yielded good result through classical plant breading whereas now genetic engineering should solve the problems of crops from abiotic and biotic stress challenges. Biotechnology as well as marker assisted breeding would quickly improve the crop selection & cultivation for quality yield & pest resistance.

Bio-Diversity should be protected by way of intensive agriculture only to maintain genetic pool in the ecosystem for phylogenetic DNA sequencing, etc.

'Green Revolution' should lead us to 'Gene Revolution' through Genomic approach, QTL mapping, marker assisted breeding & genetically modified crop development etc.

ISAAA Brief 38-2009- “The development and regulation of Bt Brinjal in India” by Mr. Bhagirath Choudhary and Ms. Kadambini Gaur was released by Prof. Montagu and the first copy of the same was received by Prof. Chopra.

This ISAAA Brief 38 is a comprehensive review of all aspects of the cultivation in India of the important vegetable brinjal, also known as eggplant or aubergine. Importantly, the Brief summarizes the development, status and content of the extensive regulatory dossier in India for biotech Bt brinjal, which confers resistance to the most important insect-pest of brinjal, fruit and shoot borer (FSB).”

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

(L to R) Prof. Chopra, Mr. Bhagirath Choudhary, Prof. Arjula Reddy and Prof. Montagu

Prof. Saedler

Prof. Montagu

Dr. Tuberosa

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

FOOD TECHNOLOGY: HUMAN HEALTH & SAFETY Chairman: Dr. Sesikeran, Director, National Institute of Nutrition, Hyderabad Speakers: 1. Dr. G. Sarwar Gilani, Senior Research Scientist, Nutrition Research Division, Health Canada, Government of Canada 2. Dr. Erik Boy, Nutrition coordinator, Global Research Program, HarvestPlus, USA Biotechnology should be tuned to increases safe Bio-Active peptides in crops for potential promotion of health. Suitable analytical techniques for determining the levels of Bio-Active peptides in foods & biological samples (blood) are needed. Industries can manufacture & market functional foods or nutraceuticals containing Bio-Active peptides. The density of vitamins & minerals in food staples for poor can be increased by transgenic techniques, a process known as Bio-fortification.

Bio Safety is a major concern. Risk assessment, Risk-Benefit ratios and Risk management are the initiate goals of Bio safety studies. Novel protein's toxicity in plants, human, live stock and its allergenic potential as well as intended affected should be properly tested to establish Bio-Safety.

Dr. Sesikerann

Dr. Sarwar Gilani

Dr. Eric Boy

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

SEED TECHNOLOGY Chairman: Dr. P. Vidhyasagar, Chairman & Managing Director, Vibha Agrotech Ltd, Hyderabad Speakers: 1. Dr. P. Vidhyasagar, Chairman & Managing Director, Vibha Agrotech Ltd, Hyderabad 2. Dr. Paresh Verma, Managing Director, Bioseed Research Pvt. Ltd. Hyderabad

Seeds of improved varieties and hybrids of field crops, horticulture crops, and vegetables using improved agribiotechnological practice should be produced in larger quantity to cater to the need for the extensive and intensive cultivation for higher quality yield. Hence, seed technology should emerge an important industry in all the developing countries.

Dr. Vidhyasagar

Dr. Paresh Verma

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

PHYTO-PHARMACEUTICALS Sponsored by: Pragati Green Meadows, Hyderabad and Kashyup Life Sciences, Hyderabad Chairman: Dr. G.B.K. Rao, Chairman and Managing Director, Pragati Green Meadows and Resorts Ltd, Hyderabad Speakers: 1. Dr. J. L. N. Sastry, Director, Pragati Ayushman Pvt. Ltd. Co., Hyderabad 2. Dr. Yamini Bhusan Tripathi, Banaras Hindu, University, Varanasi 3. Dr. Abdul Manan, Haruan Research Group, Department of Biomedical Sciences, University Putra, Malaysia Plant genome research programme & Biotechnology should identify plants and their molecules for their pharmaceutical effect and drug discovery to combat most commonly prevailing human ailments. Concept of “FARMS TO PHARMA” should be adopted upkeeping the Bio-Diversity of location. Novel poly herbals food supplements for diabetes should be manufactured using molecular approach explaining the applicability of Ayurvedic Neutraphysical model. Heritage or Bio-Diversity should be maintained by adopting Ethno-pharmacology drug discovery. Organic farming would always improve the pharmaceutical nature of crops.

Kasyap life sciences Ltd. company will release a software on “ BOTANICULE” detailing the pharmaceutical aspects of 2000 plants and 1.5 lakh molecules facilitating scientists to effective uses the seauty resources (critical) integrating the knowledge available at cheaper cost. Department of Biotechnology, Govt. of India would extend financial assistance for understanding “SMALL BUSINESS INNOVATIVE PROJECT”.

Dr. Manan Dr. Rao

Dr. Tripathi

Dr. Sastry

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

BIO FUELS Chairman: Dr. Shriram, Tata Chemicals Ltd., Hyderabad Speakers: 1.

2.

3.

4.

Dr. Taher Abbasi, Co-founder and CEO, Cellworks Group Inc., CA, USA Dr. Belum V.S. Reddy, Principal Scientist (Sorghum Breeding), ICRISAT, Hyderabad Dr. Yan Hong, JOil (S) Pte. Ltd., Singapore Prof. Pogaku Ravindra, School of Engineering and Information Technology, University of Malaysia, Malaysia

Based on “Food Vs Fuel” and “Availability Vs Affordability” concept, agri-biotechnology should develop plants for their increased ethanol production using non food crops & marginal. Waste land Jatropha, Pongamia and Sweet Sorghum were identified recently & cultivated for energy values. Difficulty in successful exploitation of Jatropha was discussed in detail.

High through-put Re-Engineering methodology using virtual strain along with some example case studies was elaborated.

Dr. Yan Hong

Dr. Taher Abbasi

Mr. Shriram

Dr. Belum Reddy

Prof. Ravindra

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

ANIMAL IMPROVEMENT & GENOMICS Chairman: Dr. Lalji Singh, Director, CCMB, Hyderabad Speakers 1. Dr. Morris Agaba, International Livestock Research Institute, Kenya 2. Dr. Giri, Genomics Biotech Ltd, Hyderabad 3. Dr. Satish Kumar, Dy. Director, CCMB, Hyderabad New opportunities for understanding and exploiting livestock diversity were explained in the wake of genomics & ILRI measures for phenotype measurements. Domestic Buffalo Genomics for genetic enhancement was highlighted for its opportunities and challenges with reference to quality yield data availability. Importance of use of molecular approaches for nematode studies was discussed.

Dr. Lalji Singh

Dr. Giri

Dr. Morris Agaba

Dr. Satish Kumar

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

ANIMAL BIOTECHNOLOGY: DIAGNOSTICS & VACCINES Chairman: Dr. Morris Agaba, International Livestock Research Institute, Kenya Speakers 1. Dr GS Reddy, CGM, IIL, Hyderabad 2. Dr. D. K. Dey, General Manager (Biotechnology), Globion Ltd, Hyderabad Biotechnology and Bio-Terrorism promote the development of vaccines of safety known for their reactogenicity. Recombinant protein, viral vector, DNA technologies were elaborated as well. Salmonella control through vaccination in poultry was explained with preventive as well as control strategies.

Dr. Reddy

Dr. Dey

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

AGRI-BIOTECH PLATFORMS: PRODUCTS AND SERVICES Chairman: Dr. S. R. Rao, Scientist G, DBT, Govt. of India, New Delhi Speakers Dr. Peter Langridge, CEO, Australian Center for Plant Functional Genomics, University of Adelaide, Australia Dr. Kiran K. Sharma, Principal Scientist, Genetic Transformation Lab, ICRISAT The unique concept of translational platform to promote the plant transgenic technologies into value added products for commercial use through public-private sector partnerships was elaborated. This could be very important concept in advancing the agri-biotechnology in the developing countries by addressing various constraints in translating the concepts of biotechnology visible products through public-private sector partnerships. This platform is an entity that will serve to evaluate the potential genetic engineering options and advance these in a focused way, to meet specific objectives for enhancing agricultural productivity.

Such platforms will not only help the public sector institution but also the small and medium sector seed companies in taking the fruits of agri-biotechnology to the most important stakeholders, the resource-poor farmers.

(L to R): Dr. S. R. Rao, Dr. Peter Langridge and Dr. Kiran Sharma

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

VALEDICTORY SESSION The event concluded with the valedictory session, which had Dr. Manel Balcells, Hon'ble President, BioRegion of Catalonia, Former Minister of Research and Innovation, Govt. of Catalonia, Spain as the Chief Guest and presided by Prof. Seyed E Hasnain, Vice Chancellor, University of Hyderabad, Chairman, AP Biotech Advisory Council and BioAsia 2009 Advisory Board, in the presence of Mr. B. P. Acharya, I.A.S., Chairman and Managing Director, APIIC, Hyderabad, Dr. William Dar, Director General, International Crop Research Institute for Semi Arid Tropics (ICRISAT), Hyderabad.

Dr. Reddanna, Professor, School of Life Sciences, University of Hyderabad and Convener, Technical Committee of BioAsia 2009, presented a brief report on the highlights of BioAsia 2009 followed by Dr. Momme Christian Velmede, Managing Director, PharmABC and Biopartnering Associate of BioAsia 2009 on the B2B platform of BioAsia 2009.

During this session a Memorandum of Understanding was signed between BioCat (Spain), Federation of Asian Biotech Associations (Hyderabad) and Andhra Pradesh Industrial Infrastructure Corporation (Hyderabad) for cooperation in various areas of Biotech/ Biopharma space.

Mr. Acharya addressed the gathering on the significance of this Memorandum.

Further, as the chairman of the organizing committee of BioAsia, he announced the dates for BioAsia 2010: The Global Biobusiness Forum, which has been scheduled for February 3-6, 2009 at Hyderabad. This was followed by the Guest of Honour Address by Dr. William Dar. Later the BioAsia Innovation Award INR 1 Lac (Rupees one lac only) and a citation to Dr. Sunil Kumar Verma of CCMB, Hyderabad for his innovative research work on “Novel Universal technique to establish the identity of enormous number of animal species for forensic application”and BioAsia Young Minds Award consisting of INR 50, 000 (Rupees fifty thousand only) and a citation awarded to Ms. Abinaya of standard XII from Sri Sankara Senior Secondary School, Chennai for her novel conceptual idea titled “Project on Marine Actinomycetes”. Besides, BioAsia Exhibition Awards were presented for best exhibits to Vibha Seeds, Hyderabad (Winner), Lonza, Switzerland (First Runner Up) and Matrix, Hyderabad (Second Runner Up).

Dr. B. S. Bajaj, Convener, BioAsia 2009, Chairman, AIBA-SC and Secretary General, FABA delivered the vote of thanks.

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

Recommendations emerged out of BioAsia-2009: The Global Biobusiness Forum 1. BioAsia 2009 has been very relevant, informative and provides a platform for new business avenues.

2. BioAsia should include various aspects of Food Processing Industry in the next event. If required 2-3 sessions can be dedicate to Food Processing Industry and also Exhibition.

3. Food Processing Industry is coming up in India but it is far behind than this industry in Europe & USA. Needs to be, accelerated through such events.

4. Food Processing Industry should give more attention to the safety of processed food for health of human being.

5.

Such events should take place more frequently serving the noble cause of integrating all the concerned for the best utilization of the all resources on hand to make this earth peaceful and plentiful.

6. BioAsia 2010 should focus on the indigenous aspects of Hyderabad in the Biotech sector like Nutraceuticals, Veterinary, etc.

7. To improve the industry exhibition, a partnership could be formed with HITEX and the exhibition could be increased in size and attendance and the number of stalls. It is suggested that FABA initiate the discussion with HITEX to check the viability of the same.

8. That the number of students attending the conference could be increased to drive further interest and participation.

9. It was informed that Hyderabad is also the seed capital of India. It was suggested that more seeds companies should be invited to participate in BioAsia 2010. It was further suggested that the sessions on seed technologies and business could be increased.

10. Green Biotechnology (Environmental Biotechnology) should also be considered for BioAsia 2010.

11. BioAsia 2009 has been very useful in attracting a couple of Biopharma majors for setting up units in Hyderabad. This lead should be followed for faster development of Biotechnology in India.

12. The Innovation and Young Minds awards should be publicized more outside Hyderabad / Andhra Pradesh.

13. That the exhibitors should be given a certain amount free entry passes well in advance so that they can invite people to come and visit their stall and the exhibition.

14. The committee should consider organizing some periodic events under the BioAsia umbrella like seminars, networking meets, etc. during the year.

15. BioAsia should include more scientific substance and much less time spent on introductions and presentations of mementos. This is not an academic ceremony it's a business meeting.

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

(L to R): Dr. William Dar, Mr. Acharya, Dr. Balcells, Dr. B. S. Bajaj and Prof. Hasnain during the exchange of the memorandum of understanding

(L to R): Dr. William Dar, Mr. Acharya, Dr. Verma, Ms. Abinaya, Prof. Hasnain, Dr. Balcells, Prof.

Reddanna and Dr. Bajaj

Special Events at BioAsia 2009

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

BIOPARKS SESSION Sponsored by ICICI Knowledge Park & SP Biotech Park Theme: “How many is too many: Sustainability of Biotech Parks in India�

BioParks 2009 was organized as a pre-conference workshop of BioAsia2009 at ICICI Knowledge Park (IKP). 60 delegates from different part of the world such as Iran, Malaysia, USA, Germany and India actively participated in the workshop.

Ms. Deepanwita Chattopadhyay, MD & CEO, IKP set the tone of the discussion through a brief presentation on the Biotech Park status in India. She briefed the participants that in India, 8 parks are operational, 3 parks will be operational soon and over 10 parks are being planned in various part of India, and invited discussion on how to ensure that so many Parks survive. She also shared her experience of running a Life Science Park for the past 9 years and the important of life science clusters. After the presentation by Ms. Chattopadhyay, the floor was open for discussions and questions where different issues were raised and discussed by the delegates.

A Malaysian delegate started the discussion with the issue of advantages of India and the government's role in promoting biotech parks. Ms. Chattopadhyay briefed him about the National Biotech Policy, prevailing ecosystem for biotech research and available qualified talent pool. Mr. Damodhar Sharma, IAS, Rajasthan Government informed the delegates that support from government such as land, policy, incentives for companies to set up their units in the biotech parks etc. play a key role. Mr. Prasanta Biswal, CEO, International Biotech Park, Pune shared his views on the advantages. He briefed that strategy for the growth of the companies, sustainability of park as well as tenants, demand and supply of experts, regional advantages, common facilities such as effluent treatment, analytical instruments and funding available for start-ups are important.

Dr. P K Seth, CEO, Lucknow Biotech Park shared his thoughts on how many parks would be seen as too many. He suggested that while Incubators to support start-ups can be as many as possible but number of parks should be limited.

Ms Chattopadhyay explained how difficult it would be to set up a stand alone biotech park without elements of a cluster in that region. The states considering setting up Biotech Parks should carefully identify the needs of the area and availability of resources be it human or raw materials. A park without an existing biocluster may not be viable. Dr. Marwaha from Punjab Biotech Park, briefed about the knowledge cluster and knowledge city being planned in Mohali which will cater to agribiotech sector, post harvest management of crops as well as biopharmaceuticals.

Col. Sandhu, VC of a private university in Hissar, Haryana described his plans for a university based biotech park. Dr Kaustabh Panda, Head of the Department, Biotechnology,

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

Calcutta University was keen to understand how a biotech park could be planned where there is no dominant biotech industry but good academic research and innovation potential.

The delegation from Iran led by Dr Halle Hashimi was keen to understand the role of government and universities in incubators and biotech parks. Ms. Janet from Bell Boyd & Lloyd, USA shared her experience about the US incubators and resources available for startup companies. Ms. Chattopadhyay added that understanding the start-ups, their problems and then providing the customized support services are need of an hour. Ms. Chattopadhyay also talked about the changes in patent regime and innovation ecosystem at large in India.

Mr. Gopala Krishnan, CEO, S P Biotech Park shared his thoughts on biotech parks and how many would be too many. He suggested that keeping in mind the current economic downturn, sustainability of Parks would be difficult if numbers of parks are more. He also made a point that market demand will slow down and customers expectations will be up and it would be tough to sustain if number of parks goes up and that the vision and strategy of biotech parks would play a crucial role to sail through the hard times.

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

CEO CONCLAVE Sponsored by Ersnt & Young Pvt. Ltd and UK Trade & Investment Theme: Taking Biotechnology Industry to the Next Level The CEO Conclave is a premiere event organized by Ernst and Young's India Health nd Sciences practice in association with UKTI on February 2 , 2009. The event provides a platform for distinguished leaders from across the world in sharing their experiences and insights with the audience.

The CEO Conclave was a part of BioAsia 2009, the international conference on Biotechnology. BioAsia, an annual premier bio-pharma event, had been conceptualized to exchange views on the opportunities and challenges that lie before the Indian Biotechnology / Pharmaceuticals industry seen from the perspective of senior management and leaders in this field.

The eminent panelists comprised of Dr Stefan Borgas (CEO Lonza), Prof Marc Van Montagu (Chairman, Institute of Plant Biotechnology for Developing Countries, Belgium), Dr Villoo Morawala-Patell (Founder Chairman and MD Avesthagen), Dr Krishna Ella (Chairman and Managing Director, Bharat Biotech), Dr. Robert W Naismith, Chairman and Managing Director, Roosevelt Capital Partners LLP, USA and Dr Narender Matena (Corporate Development, Biological E). Hitesh Sharma (Partner and National Health Sciences Leader, Ernst & Young) moderated the discussion. Kali Prasad (Partner and South India Health Sciences Leader, Ernst & Young) had set the ball rolling with an introduction followed by a presentation by Murali Nair (Partner Ernst & Young) on the theme of the discussion for this year, 'Taking Biotechnology Industry to the Next Level'.

The conclave focused on the challenges of building a thriving biotechnology business in an uncertain environment. The panel discussion specifically looked at innovative ideas pertaining to: • • •

industry academia linkages alliances amongst companies in order to strengthen pipelines and reduce timelines needed for bringing a drug to market the role of the Government and other stakeholders for providing better infrastructure and a clear regulatory environment for a thriving biotechnology industry

The CEO Conclave 2009 witnessed a participation of over 250 members comprising of distinguished CEO's, eminent personalities from scientific community, publicly funded institutions and academia.

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

(L to R) Dr. Matena, Dr. Villoo Patell, Mr. Borgas, Dr. Ella, Prof. Montagu, Dr. Naismith, Mr. Nair, Mr. Sharma and Mr. Prasad

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

Expert's Comments “It surely was very stimulating to meet so many excellent Indian colleagues and to see how motivated they are develop to Bio-Business. I noticed that BioAsia 09, attracted many SME's from the healthcare sector.

For them high value chemicals from medicinal plants, the development of neutraceuticals and the processing of medicinal plants, a well established tradition all over Asia, all are an opportunity for biotechnological innovation” - Prof. Marc Van Montagu, Founder Chairman, Institute of Plant Biotechnology in Developing Countries, Belgium

“I was very honored to be part of BioAsia 2009. It was a terrific event. I was impressed by the energy level in the room that evening. It was well attended and the audience was very engaged. The willingness of the participants to partner with us was exceptional and I am truly delighted by the number of great connections we made at BioAsia and throughout our visit. In addition, the follow up to the event has been superb” - Dr. Martin Mackay, President, Pfizer Global Research & Development, USA

“I have attended and organized few events in the past. This event's organization and arrangements were very well done” - Dr. Taher Abbasi, CEO, Cell Works Group, USA

“I found the conference very rewarding professionally and I was pleased to make some new professional contacts. Once again, I am most grateful for receiving your gracious hospitality” - Dr. Sarwar Gilani, Health Canada, Government of Canada

“The conference has given an excellent opportunities to small firms like ours to get exposure to India and Global companies, network and develop business opportunities. Wish you all the best for 2010” - Dr Sudhir Reddy, Managing Partner, Insight Bioventures India

“I would like to see more scientific substance and much less time spent on introductions and presentations of mementos. This is not an academic ceremony its a business meeting” - Dr. Reid Leonard, Executive Director, External Research and Licensing, Merck & Co., USA

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

“I found the scientific sessions that I attended of very high quality and some of the speakers were extremely informative and engaging. All in all I think it was 3 days well spent and thanks once again for making it possible” - Ravi C Dasgupta, Head - Group HR, Biocon Ltd, Bangalore

“BioAsia 2009 has been very relevant, informative, educative and provides a platform for new business avenues” - Dr. S. V. Rama Rao

“Thank you very much for the invitation to speak at and participate in BioAsia 2009. It was a great experience and I am very grateful for the opportunity” - Dr. John M Hyde, Chairman, Hyde Engineering & Consulting Inc., USA

“Sincerely thanking you for making my attending BioAsia 2009 and staying in Hyderabad a pleasant one” - Dr. Abdul Manan, Department of Biomedical Sciences, Putra University, Malaysia

“It was a wonderful event and getting such a prestigious award was an unforgettable experience for me! I am sure this award would open several ways for me and my scientific career in the coming times. Thank you very much” - Dr. Sunil Kumar Verma, Centre for Cellular and Molecular Biology, Hyderabad

“A small note with a big thank you!! Thanks to the tremendous efforts put in by FABA, BioAsia, esp the CEO Conclave was an outstanding success. Not just the panel discussions, but all the elements of the event turned out well” - Mr. Surajit Banerjee, AVP - Sales & Business Development, Client Service & Accounts, Ernst & Young Pvt. Ltd

“Congratulations on the successful completion of the Bio-Asia 2009 Global Bio Business Forum and we wish that many more to take place serving the noble cause of integrating all the concerned for the best utilisation of the all resources on hand to make this earth peaceful and plentiful. We also co-operate in your earnest endeavor in our own humble way” - Dr. S. Bhaskaran, Dept. of BioSciences, Sri Sathya Sai University, Prashanthinilayam

“It was indeed a great experience for me to be part of BioAsia2009” - Ms. Victoria, Science & Innovation Adviser, UK Trade & Investment, Bangalore

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

BIOASIA 2009 COMMITTEES ADVISORY BOARD Chairman: Prof. Seyed E Hasnain, Vice Chancellor University of Hyderabad, Chairman, AP Biotech Advisory Council, Chairperson, India Chapter of FABA and Patron, AIBA-SC Members: 1. Mr. Peter T Hassan, Advisor (Industries), Govt. of A.P and Honorary ConsulGeneral for the Russian Federation in Hyderabad 2. Mr. B. P. Acharya, l.A.S, Chairman & Managing Director, Andhra Pradesh Industrial and Infrastructure Corporation Ltd and Patron, FABA 3. Mr. Sam Bob, l.A.S, Principal Secretary to the Government of AP, Industries & Commerce Department 4. Prof. M. V. Rao, MLC & Former Vice Chancellor, ANGRAU 5. Mr. Indrasain Reddy, MLC 6. Dr. Anwar Nasim, President, FABA and Chairman, National Commission of Biotechnology, Pakistan 7. Dr. Sheela Bhide, I.A.S, Chairman & Managing Director, India Trade Promotion Organisation, New Delhi 8. Dr. Kiran Mazumdar Shaw, CMD, Biocon Ltd, Bangalore 9. Dr. Villo Morawala Patell, Founder, Chairperson & Managing Director, Avestha Gengraine Technologies Pvt Ltd., Bangalore 10. Dr. William D Dar, Director General, ICRISAT 11. Mr. Utkarsh Palnitkar, Partner & Head, Advisory Services, E & Y 12. Mr. Vivek Singhal, President, All India Biotech Association, New Delhi and Adviser, FABA, New Delhi 13. Dr. Lalji Singh, Director, Centre for Cellular and Molecular Biology and Patron, AIBA-SC 14. Dr. Robert Naismith, Chairman & CEO, Roosevelt Capital Partners, LLC, PA, USA 15. Dr. Abbas S. Lotfi, Vice President, FABA & Director, National Institute for Genetic Engineering & Biotechnology (NIGEB), Iran 16. Prof. Dr. Kazuo Watanabe, Vice President, FABA & Gene Research Center, University of Tsukubam, Japan ORGANIZING COMMITTEE Chairman: Mr. B. P. Acharya, l.A.S, Chairman & Managing Director, Andhra Pradesh Industrial and Infrastructure Corporation Ltd and Patron, FABA Convener: Dr. B. S. Bajaj, Secretary General (FABA) & Chairman (AIBA-SC) Members: 1.

Mr. Neerabh Kumar Prasad, l.A.S, Commissioner of Industries

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

2. Dr. Ashok K Sadhukhan, Director, Saamya Biotech Ltd, Treasurer, FABA and Vice Chairman AlBA- SC 3. Prof. P. Reddanna, School of Life Sciences, University of Hyderabad, Member Secretary, India Chapter of FABA and Vice Chairman, AIBA-SC 4. Ms. Deepanwita Chattopadhyay, CEO, ICICI Knowledge Park and Executive Secretary, FABA 5. Ms. Anuradha Acharya, CEO, Ocimum Biosolutions Ltd 6. Dr. Gopal Krishna, CEO, Shapoorji Pallonji Biotech Park 7. Dr. V. Satyanarayana - MD, Sipra Labs Pvt Ltd 8. Mr. Sarat Naru, Managing Partner, APIDC Venture Capital 9. Mr. Kali Prasad, Leader (South), Health Science Industry Initiative, E&Y 10. Mr. Vishal Goel, Vice President & Country Manager (India), Alexandria Real Estate Pvt. Ltd 11. Mr. V. Prasanna Kumar, Jt. Director, Commissionerate of Industries, Govt. of AP 12. Dr. Sibani Sadhukhan, Joint Secretary FABA 13. Dr. Vijaya Kumar, Associate Professor, NIMS 14. Mr. Shreedhar Anapurapu, Advisor to the MD, Celestial Labs 15. Mr. N. Shakthi Meyyappan, Manager (Biotechnology), FABA 16. Mr. Aakula Rajesh, Executive (Commercial), FABA TECHNICAL COMMITTEE Chairman: Prof. Seyed E Hasnain, Vice Chancellor, University of Hyderabad, Chairperson, AP Biotech Advisory Council, Chairperson, India Chapter of FABA and Patron, AIBA-SC Convener: Prof. P. Reddanna, School of Life Sciences, University of Hyderabad, Member Secretary, India Chapter of FABA and Vice Chairman, AIBA-SC Members: 1. Prof. D. Balasubramanian, Director (Research), L V Prasad Eye Institute 2. Dr. K. I. Varaprasad Reddy, Chief Executive Officer, Shantha Biotechniques ltd. and Patron, AIBA-SC 3. Dr. Krishna M Ella, CMD, Bharat Biotech International Ltd. and Patron, AIBA-SC 4. Dr. J. S. Yadav, Director, Indian Institute of Chemical Technology 5. Dr. J Gowrishankar, Director, Centre for DNA Fingerprinting and Diagnostics 6. Dr. B. S. Bajaj, Secretary General (FABA) & Chairman (AIBA-SC) 7. Prof. P. R. K Reddy, Former Dean, School of Life Sciences, University of Hyderabad 8. Dr. Kaiser Jamil, Research Director, Indo-American Cancer Hospital 9. Dr. Prakash V Diwan, Project Director, NIPER 10. Dr. Sashi Vardhan, Scientist, IICT 11. Dr. Arabinda Choudhry, Scientist, IICT 12. Prof. S. Dayananda, Head, Dept. of Animal Sciences, University of Hyderabad 13. Prof. K. Anand Kumar, Dept. of Biotechnology, University of Hyderabad 14. Prof. V. Lakshmipathi, Guest Professor, NIPER

R

Report

FEBRUARY 2 - 4, 2009, HYDERABAD, INDIA

AGRIBIOTECH COMMITTEE Chairman: Prof. A. R. Reddy, Vice Chancellor, Yogi Vemana University, Kadapa, AP Convener: Dr. Kiran K. Sharma, Principal Scientist, Genetic Transformation Lab, ICRISAT Members: 1.

2.

3.

4.

5.

6.

7.

8.

9.

10.

11.

Dr. S. R. Rao, Advisor, Department of Biotechnology, Govt. of India, New Delhi Prof. Raghava Reddy, Vice Chancellor, ANGRAU Dr. P. Vidhyasagar, Chairman & Managing Director, Vibha Agrotech Ltd Dr. B. Sesikeran, Director, National Institute of Nutrition Dr. B. S. Bajaj, Secretary General, Federation of Asian Biotech Associations Dr. T. N. Ramanaiah, Manager (Biotech Affairs), PHI Seeds Mr. SM. Karuppanchetty, Dy. Chief Operating Officer, Agri Business Incubator, ICRISAT Dr. Satish Kumar, Dy. Director, CCMB and Member of Executive Committee, FABA Dr. Ramesh Aggarwal, Scientist, CCMB Dr. G. Anuradha, Head (Research), Dept. of Biotechnology, ANGRAU Prof. P. Appa Rao, Head, Dept. of Plant Sciences, University of Hyderabad and Member of Executive Committee, AIBA-SC

EVENT ASSOCIATE Mr. Sagar Pingali, Director, Catpro Events and Entertainments Ltd, Hyderabad B2B ASSOCIATE Dr. Momme Christian Velmede, Managing Director, PharmABC, Germany

PUBLIC RELATIONS AGENCY: M/s. SlokaPR, Hyderabad